Pongamol

Synonyms: Lanceolatin C
Pongamol(Lanceolatin C)是一种具有口服活性的黄酮类化合物,对 PTPase-1B 的 IC50 为 75 μM、Ki 为 58 μM,对肠道 α-Glycosidase 的 IC50 为 103.5 μM,可降低细胞中 IL‑1β、TNF‑α、COX‑2 和 iNOS 的释放,逆转 NF‑κB 的核转位,上调 Beclin 1 及 LC3 Ⅱ/LC3 Ⅰ 水平,通过提高骨骼肌细胞表面的 GLUT4 水平促进葡萄糖摄取,通过抑制 FAK/Akt-mTOR 信号通路抑制上皮-间质转化,通过激活 MAPKs/Nrf2 信号通路抑制神经元细胞神经毒性、抑制细胞凋亡(Apoptosis)并延长秀丽隐杆线虫寿命,具有抗菌活性,在糖尿病小鼠模型中发挥降血糖作用,并在阿尔茨海默病小鼠模型中通过抑制 Akt/mTOR 信号通路减轻氧化应激、神经炎症、Aβ 沉积及 Tau 蛋白(Tau Protein)过度磷酸化并恢复自噬(Autophagy)功能,可用于阿尔茨海默病、2 型糖尿病、非小细胞肺癌及餐后高血糖的相关研究。
产品编号: MS-W76759 纯度: 99.81% CAS No.: 484-33-3 分子式: C18H14O4 分子量: 294.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Pongamol(Lanceolatin C)是一种具有口服活性的黄酮类化合物,对 PTPase-1B 的 IC50 为 75 μM、Ki 为 58 μM,对肠道 α-Glycosidase 的 IC50 为 103.5 μM,可降低细胞中 IL‑1β、TNF‑α、COX‑2 和 iNOS 的释放,逆转 NF‑κB 的核转位,上调 Beclin 1 及 LC3 Ⅱ/LC3 Ⅰ 水平,通过提高骨骼肌细胞表面的 GLUT4 水平促进葡萄糖摄取,通过抑制 FAK/Akt-mTOR 信号通路抑制上皮-间质转化,通过激活 MAPKs/Nrf2 信号通路抑制神经元细胞神经毒性、抑制细胞凋亡(Apoptosis)并延长秀丽隐杆线虫寿命,具有抗菌活性,在糖尿病小鼠模型中发挥降血糖作用,并在阿尔茨海默病小鼠模型中通过抑制 Akt/mTOR 信号通路减轻氧化应激、神经炎症、Aβ 沉积及 Tau 蛋白(Tau Protein)过度磷酸化并恢复自噬(Autophagy)功能,可用于阿尔茨海默病、2 型糖尿病、非小细胞肺癌及餐后高血糖的相关研究。

生物实验数据

生物活性 Pongamol (Lanceolatin C) is an orally active flavonoid that inhibits PTPase-1B with an IC50 of 75 μM and a Ki of 58 μM and intestinal α-Glycosidase with an IC50 of 103.5 μM, reduces the release of IL‑1β, TNF‑α, COX‑2, and iNOS in cells, reverses NF‑κB nuclear translocation, upregulates Beclin 1 and LC3 Ⅱ/LC3 Ⅰ levels, promotes glucose uptake by increasing GLUT4 levels on the surface of skeletal muscle cells, inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway, inhibits neurotoxicity in neuronal cells, suppresses apoptosis (Apoptosis), and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway, exhibits antibacterial activity, exerts hypoglycemic effects in diabetic mouse models, and in Alzheimer's disease mouse models attenuates oxidative stress, neuroinflammation, Aβ deposition, and Tau protein (Tau Protein) hyperphosphorylation and restores autophagy (Autophagy) function by inhibiting the Akt/mTOR signaling pathway, and can be used for research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer, and postprandial hyperglycemia.
体外研究
(In Vitro)

Pongamol (25-100 μM, 预孵育 1 h,随后 LPS 刺激 24 h) 抑制 BV2 小鼠小胶质细胞中 LPS (MS-X54539) 诱导的 NO 释放,通过降低 IκB 磷酸化并阻断 NF-κB 核转位,抑制 细胞中 LPS 诱导的 NF-κB 通路激活,下调细胞中促炎基因 (IL-1β、TNF-α、iNOS、COX-2) 的表达。
Pongamol (100 μM, 预处理 1 h,随后给予 LPS 刺激 24 h) 可降低 LPS 刺激的 BV2 小鼠小胶质细胞中促炎蛋白 (IL-6、IL-1β) 的水平,并上调自噬标志物 (Beclin 1、LC3 II/LC3 I) 的表达,且这些效应依赖于 Akt 通路。
Pongamol (0-10 μM; 0-16 h) 增加 L6-GLUT4myc 肌管细胞的基础及胰岛素叠加型葡萄糖摄取,通过激活 PI3-激酶活性提升细胞表面的基础型及胰岛素增强型 GLUT4 转位,增强肌管中 Insulin (MS-R27415) 诱导的 AKT (Ser-473) 磷酸化。
Pongamol (0-100 μM, 2 h) 提升经 H2O2 诱导的 PC12 细胞存活率,降低细胞中 LDH 的释放,抑制细胞凋亡,恢复线粒体膜电位,降低促凋亡蛋白水平并提高抗凋亡蛋白水平,抑制细胞中 MAPKs 信号通路激活 (降低 p-ERK、p-JNK 及 p-p38 水平),提升 GSH 水平降低 ROS 水平,促进 Nrf2 核转位、上调下游抗氧化基因表达及直接结合 Keap1,激活 Nrf2/HO-1 信号通路。
Pongamol (0-100 μM; 24-48 h) 可呈剂量依赖性降低 H460 非小细胞肺癌细胞的存活率,抑制细胞的增殖、锚定非依赖性生长、迁移、侵袭能力。
Pongamol (25-100 μM; 24 h) 在 H460 非小细胞肺癌细胞中上调上皮标志物 E-cadherin,下调间质标志物 N-cadherin、波形蛋白 (vimentin)、Slug 和 Snail,抑制 细胞中 FAK/Akt-mTOR 信号通路的激活,降低磷酸化 FAK、Akt 和 mTOR 的水平。
Pongamol (Compound 1) 在无细胞实验中抑制重组蛋白酪氨酸磷酸酶-1B (PTPase-1B),其 IC50 为 75 μM,Ki 为 58 μM。
Pongamol (Compound 6) 可强效抑制大鼠肠道 α-葡萄糖苷酶,其 IC50 为 103.5 μM。
Pongamol 对大肠杆菌和金黄色葡萄球菌具有活性 (MIC 分别为 8 和 6 µg/mL)。

Western Blot Analysis

Cell Line: LPS-stimulated BV2 mouse microglia
Concentration: 25, 50, 100 μM
Incubation Time: 1 h pre-incubation, followed by 24 h LPS stimulation
Result: Dose-dependently decreased the p-IκB/IκB ratio in cytoplasmic fractions and significantly inhibited the nuclear translocation of p-NF-κB/NF-κB relative to the LPS-only model group.

Real Time qPCR

Cell Line: LPS-stimulated BV2 mouse microglia
Concentration: 25, 50, 100 μM
Incubation Time: 1 h pre-incubation, followed by 4 h LPS stimulation
Result: Dose-dependently reduced the mRNA expression levels of IL-1β, TNF-α, iNOS, and COX-2 relative to the LPS-only model group.

Western Blot Analysis

Cell Line: LPS-stimulated BV2 mouse microglia
Concentration: 100 μM
Incubation Time: 1 h pre-incubation, followed by 24 h LPS stimulation
Result: Significantly decreased IL-6 and IL-1β protein expression, and increased Beclin 1 and LC3 II/LC3 I protein levels relative to the LPS-only model group; these effects were reversed by co-treatment with wortmannin.

Western Blot Analysis

Cell Line: Differentiated L6-GLUT4myc skeletal muscle myotubes
Concentration: 10 μM
Incubation Time: 16 h
Result: Significantly potentiated insulin-stimulated AKT (Ser-473) phosphorylation to 7.8-fold of control basal.

Cell Viability Assay

Cell Line: Highly differentiated PC12 cells
Concentration: 5-100 μM (5-80 μM for H2O2 co-treatment; 5, 10, 20, 40, 60, 80, and
100 μM pongamol)
Incubation Time: 2 h pretreatment, followed by 24 h H2O2 co-treatment; duration of assay (for pongamol alone testing)
Result: Exhibited no significant effect on PC12 cell survival when used alone.
Increased cell survival in a concentration-dependent manner, with survival rates increased by 17.16%, 29.63%, and 44.29% at 20, 40, and 80 μM, respectively, when used to pretreat cells before H2O2 exposure.

Cell Cytotoxicity Assay

Cell Line: Highly differentiated PC12 cells
Concentration: 20, 40, and 80 μM
Incubation Time: 2 h pretreatment, followed by 24 h H2O2 co-treatment
Result: Significantly reduced LDH release in a dose-dependent manner, with reductions of 33.16%, 50.59%, and 109.84% at 20, 40, and 80 μM, respectively, compared to H2O2-only treated cells.

Apoptosis Analysis

Cell Line: Highly differentiated PC12 cells
Concentration: 20, 40, and 80 μM
Incubation Time: 2 h pretreatment, followed by 24 h H2O2 co-treatment
Result: Reduced the proportion of early and late apoptotic cells in a concentration-dependent manner; at 80 μM, the total apoptotic rate was reduced to 7.04%, compared to 39.57% in H2O2-only treated cells.

Western Blot Analysis

Cell Line: Highly differentiated PC12 cells
Concentration: 20, 40, and 80 μM
Incubation Time: 2 h pretreatment, followed by 24 h H2O2 co-treatment
Result: Prevented the H2O2-induced increase in pro-apoptotic proteins Bax, Cyto C, Cleaved Caspase-3, and Cleaved PARP1, and prevented the H2O2-induced decrease in anti-apoptotic protein Bcl-2, resulting in a reduced Bax/Bcl-2 ratio.

Western Blot Analysis

Cell Line: Highly differentiated PC12 cells
Concentration: 80 μM
Incubation Time: 2 h pretreatment, followed by 1, 2, or 4 h H2O2 co-treatment; 2 h pretreatment, after MAPKs inhibitor pretreatment, followed by 24 h H2O2 co-treatment
Result: Reduced the H2O2-induced phosphorylation of ERK, JNK, and p38.
Inhibitors of MAPKs pathways attenuated the effect of pongamol on reducing the Bax/Bcl-2 ratio in H2O2-treated cells.

Cell Viability Assay

Cell Line: H460 non-small cell lung cancer cells
Concentration: 0, 10, 25, 50, 100 μM
Incubation Time: 24 h
Result: Reduced cell viability in a dose-dependent manner.

Cell Proliferation Assay

Cell Line: H460 non-small cell lung cancer cells
Concentration: 25, 50, 100 μM
Incubation Time: 24 h, 48 h
Result: Significantly suppressed cell proliferation at 48 h compared to control.
Significantly reduced proliferation at 50 and 100 μM compared to control.

Cell Migration Assay

...(内容过长已截断)
Cell Line: H460 non-small cell lung cancer cells
Concentration: 25, 50, 100 μM
体内研究
(In Vivo)

Pongamol (10-20 mg/kg;i.g.;每日;4 周) 可通过抑制 Akt/mTOR 信号通路,改善 D-gal/NaNO2/AlCl3 诱导的阿尔茨海默病小鼠的空间学习记忆能力,减轻氧化应激、神经炎症、Aβ 沉积及 Tau 蛋白过度磷酸化,并恢复自噬功能。
Pongamol (15-60 μM;in NGM medium;从 L1 期至成虫期/L4 期给药处理 1-5 天) 可提高表达人类 Tau 蛋白的 BR5270 秀丽隐杆线虫阿尔茨海默病模型的头部摆动活性,提示其神经元功能得到改善,增强 DA2123 秀丽隐杆线虫自噬报告模型的自噬活性,降低了表达人源 Aβ/Tau 的阿尔茨海默病秀丽隐杆线虫模型中的脂褐素沉积水平与 Aβ mRNA 表达量。
Pongamol (50-100 mg/kg;i.g.;单次给药) 在 Streptozotocin (MS-Q80520) 诱导的糖尿病大鼠中可产生显著的剂量依赖性降血糖作用。
Pongamol (100 mg/kg;i.g.;每日;连续 10 天) 可在 2 型糖尿病 db/db 小鼠中产生显著且持久的降血糖作用。

Animal Model: C57BL/6 (male)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.g.; daily; 4 weeks
Result: Significantly reduced escape latency.
Increased platform crossing frequency.
Increased time/distance spent in the target quadrant in the Morris water maze test.
Decreased hippocampal acetylcholinesterase (AChE) and malondialdehyde (MDA) levels.
Increased serum superoxide dismutase (SOD) and catalase (CAT) levels.
Alleviated neuronal disorganization and loss in the hippocampus and cortex.
Reduced Nissl body loss.
Increased tyrosine hydroxylase (TH)-positive cell counts in the hypothalamus.
Reduced neuronal nuclei (NeuN) expression in the cortex and hippocampus.
Reduced glial fibrillary acidic protein (GFAP) and β-amyloid (Aβ) positive cell counts in the cortex and hippocampus.
Inhibited Tau hyperphosphorylation in hippocampal tissue.
Downregulated mRNA expression of IL-1β, TNF-α, iNOS, and COX-2 in the hippocampus.
Increased hippocampal Beclin 1 expression.
Increased the LC3 II/LC3 I ratio.
Reduced p62 mRNA expression.
Increased Atg13 mRNA expression.
Decreased phosphorylated Akt (p-Akt) and phosphorylated mTOR (p-mTOR) protein levels in the hippocampus.
Animal Model: BR5270 (human Tau-expressing AD model); DA2123 (GFP-labeled LGG-1/LC3 autophagy reporter); UM0001 (human Aβ1-42/Tau-expressing)
Dosage: 15 μM; 30 μM; 60 μM
Administration: in NGM medium; from L1 stage through adulthood; 1-5 day treatment at L4 stage
Result: Significantly increased the number of head wiggles in BR5270 C.
elegans in a dose-dependent manner.
Significantly increased the number of LGG-1:GFP puncta in DA2123 C.
elegans in a dose-dependent manner, indicating enhanced autophagic activity.
Reduced lipofuscin deposition in UM0001 worms in a concentration-dependent manner, with the 60 μM dose producing the greatest reduction in fluorescence intensity per unit area relative to untreated worms.
Reduced Aβ mRNA expression in UM0001 worms in a concentration-dependent manner, with the 60 μM dose producing the lowest Aβ transcript levels.
Animal Model: UM0001 (human Aβ1-42/Tau-expressing)
Dosage: 15 μM; 30 μM
Administration: NGM plate supplementation
Result: Increased mRNA expression of Skn-1 and its downstream antioxidant genes Sod-1, Gcs-1, and Gst-4 in UM0001 worms in a concentration-dependent manner.
Animal Model: Sprague Dawley (male, 7-8 weeks old, 160 g, streptozotocin-induced diabetic)
Dosage: 50 mg/kg; 100 mg/kg
Administration: i.g.; single dose
Result: Reduced blood glucose by 12.8% at 6 hours post-administration.
Reduced blood glucose by 22.0% at 6 hours post-administration.
Animal Model: db/db (12-18 weeks old, 40 g, genetically diabetic)
Dosage: 100 mg/kg
Administration: i.g.; daily; 10 consecutive days
Result: Reduced blood glucose by 35.7% overall, with significant reductions observed on days 13-15 and days 17-19.
Improved glucose tolerance by 18.61% compared to controls, with significantly lowered postprandial blood glucose levels at 30, 60, 90, and 120 minutes post-load.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 294.30
分子式 C18H14O4
CAS No. 484-33-3
别名 Lanceolatin C

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 5 mg/mL (16.99 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Corn Oil: 1 mg/mL (3.4 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (16.99 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (169.89 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3979 mL16.9895 mL33.9789 mL84.9473 mL
5 mM0.6796 mL3.3979 mL6.7958 mL16.9895 mL
10 mM0.3398 mL1.6989 mL3.3979 mL8.4947 mL
15 mM0.2265 mL1.1326 mL2.2653 mL5.6632 mL
20 mM0.1699 mL0.8495 mL1.6989 mL4.2474 mL
25 mM0.1359 mL0.6796 mL1.3592 mL3.3979 mL
30 mM0.1133 mL0.5663 mL1.1326 mL2.8316 mL
40 mM0.0849 mL0.4247 mL0.8495 mL2.1237 mL
50 mM0.0680 mL0.3398 mL0.6796 mL1.6989 mL
60 mM0.0566 mL0.2832 mL0.5663 mL1.4158 mL
80 mM0.0425 mL0.2124 mL0.4247 mL1.0618 mL
100 mM0.0340 mL0.1699 mL0.3398 mL0.8495 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈